The Alpha Cognition executive discusses recent developments that positively impact the upcoming launch for ZUNVEYL.

FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.

The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

Zimmer Biomet Holdings launched a new educational campaign targeting people living with joint pain. 1 The campaign is ...

Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...

FDA recently announced new safety requirements for DPD screening in cancer patients. Kristine Ashcraft, founder and CEO of ...

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing ...

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy ...

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well ...

Aspargo Labs uses a proprietary technology platform to reformulate oral medication to liquid doses. CEO and chairman Michael ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...